Eurofins Central Laboratory announced the expansion and relocation of its US Central Laboratory Operations to the company's Pharma Services campus in Lancaster, PA.
Eurofins Central Laboratory announced the expansion and relocation of its US Central Laboratory Operations to the company's 330,000 square foot Pharma Services campus in Lancaster, PA. The consolidation of the company's Central Laboratory with its Lancaster Laboratories comes amongst the recently announced acquisitions of US bioanalytical, discovery, genomic and diagnostic laboratories. The purpose built Central Laboratory is essential to the global footprint of wholly-owned laboratory facilities in the United States, Europe,Asia and China.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
HHS Cancels Moderna Grant for Late-Stage Development of mRNA Vaccine Candidate
June 4th 2025Despite positive results from a Phase I/II trial of its investigational pandemic influenza vaccine, mRNA-1018, Moderna’s award for almost $600 million to accelerate vaccine development will be terminated.